Dermatological microbiome interventions governance

Introduction

Dermatological microbiome interventions refer to medical, cosmetic, and biotechnological treatments designed to modify, restore, or regulate microorganisms living on human skin. The skin microbiome consists of bacteria, fungi, viruses, and other microorganisms that contribute to skin health, immune responses, and protection against harmful pathogens.

These interventions include topical probiotics, prebiotics, postbiotics, microbiome transplantation research, microbial-based skincare products, and genetically engineered microorganisms developed for therapeutic purposes.

Although microbiome-based treatments offer potential benefits for conditions such as acne, eczema, psoriasis, and other inflammatory skin disorders, they raise important legal and regulatory questions. These include product classification, clinical safety, informed consent, genetic privacy, microbial containment, advertising claims, and liability for adverse reactions.

Dermatological microbiome governance therefore requires coordination between healthcare regulators, biotechnology authorities, consumer protection institutions, and data protection authorities.

Meaning and types of dermatological microbiome interventions

Dermatological microbiome interventions aim to influence the composition or activity of microorganisms present on the skin.

Major categories include:

1. Probiotic interventions: These involve applying beneficial live microorganisms intended to support skin microbial balance.

2. Prebiotic interventions: These use substances intended to support beneficial microorganisms already present on the skin.

3. Postbiotic interventions: These involve non-living microbial components or substances produced by microorganisms that may provide skin-related benefits.

4. Microbiome transplantation: This involves transferring selected microbial communities from one source to another for research or potential therapeutic purposes.

5. Engineered microbial interventions: These involve genetically modified microorganisms developed for specific biological or therapeutic functions.

Each category may require a different regulatory approach depending on its composition, intended purpose, claims, and potential risks.

Indian legal framework

1. Drugs and Cosmetics Act, 1940

The Drugs and Cosmetics Act, 1940, regulates drugs and cosmetics in India.

The classification of a microbiome-based dermatological product depends on its intended use, composition, presentation, and claims.

A product marketed for treating or preventing a disease may fall within the definition of a drug, whereas a product intended primarily for cleansing, beautifying, or altering appearance may fall within the cosmetic regulatory framework.

The applicable regulatory requirements may therefore differ significantly between therapeutic microbiome products and ordinary skincare products.

2. New Drugs and Clinical Trials Rules, 2019

These Rules establish requirements concerning clinical trials, new drugs, ethics committees, informed consent, and participant safety.

Where a dermatological microbiome intervention qualifies as a new drug or falls within another regulated category, the relevant approval and clinical research requirements must be satisfied.

3. Environment (Protection) Act, 1986

The Environment (Protection) Act and the Rules of 1989 concerning hazardous microorganisms and genetically engineered organisms may become relevant when dermatological research involves genetically engineered microorganisms falling within their scope.

Institutional biosafety and other applicable approvals may be required depending on the nature of the organism and proposed activity.

4. Consumer Protection Act, 2019

The Consumer Protection Act regulates misleading advertisements, unfair trade practices, and defective products.

Manufacturers of microbiome-based skincare products must ensure that claims concerning microbial balance, treatment benefits, and clinical effectiveness are supported by reliable evidence.

5. Digital Personal Data Protection Act, 2023

Dermatological microbiome research may involve personal information, medical records, genetic information, and identifiable research data.

Where digital personal data are processed, organisations must comply with applicable requirements under the DPDP Act, including lawful processing, security safeguards, and relevant consent obligations.

International regulatory framework

1. European Union General Data Protection Regulation (GDPR)

The GDPR provides protection for personal data, including health and genetic information. Article 9 establishes additional requirements for processing special categories of personal data.

It is relevant where microbiome studies collect identifiable health information or genetic information associated with skin microorganisms.

2. European Union Medical Device Regulation, 2017/745

The Medical Device Regulation may apply to microbiome-related products where their intended purpose and mode of action satisfy the legal definition of a medical device.

However, products that achieve their principal intended action through pharmacological, immunological, or metabolic means may fall under medicinal product regulation instead.

3. International ethical guidelines

The Declaration of Helsinki and the UNESCO Universal Declaration on Bioethics and Human Rights provide important ethical principles concerning informed consent, research participants, privacy, and scientific responsibility.

These instruments guide responsible research but should not automatically be treated as binding domestic legislation.

Major governance challenges

1. Product classification: Microbiome interventions may be classified as cosmetics, drugs, biological products, or medical devices. Incorrect classification may result in regulatory non-compliance.

2. Clinical safety: Introducing live microorganisms onto human skin may create risks involving contamination, unexpected immune responses, infection, or microbial imbalance.

3. Informed consent: Clinical participants must receive adequate information about experimental treatments, potential risks, and available alternatives.

4. Microbial resistance: Certain interventions may influence microbial communities and potentially affect antimicrobial resistance. Appropriate scientific monitoring is therefore important.

5. Privacy and biological data: Microbiome datasets may contain information that can be linked to individuals. Researchers must establish suitable confidentiality and access controls.

6. Advertising and commercial claims: Companies should not make unsupported claims that microbiome products permanently cure acne, eczema, psoriasis, or other medical conditions.

7. Long-term monitoring: The effects of microbial interventions may change over time. Regulatory frameworks should encourage appropriate post-market safety monitoring.

Important case laws

Direct Indian judicial decisions specifically concerning dermatological microbiome interventions remain limited. The following cases establish relevant principles in medical regulation, product safety, privacy, and scientific responsibility.

1. Samira Kohli v. Dr. Prabha Manchanda (2008) 2 SCC 1

The Supreme Court explained the requirements of informed consent in medical treatment. It held that consent for one medical procedure does not automatically authorise a substantially different procedure.

The decision is relevant to experimental microbiome treatments because patients must receive adequate information before undergoing innovative dermatological interventions.

2. Indian Medical Association v. V.P. Shantha (1995) 6 SCC 651

The Supreme Court examined the application of consumer protection law to medical services. It established important principles concerning the liability of healthcare professionals and medical service providers.

The judgment is relevant to microbiome-based dermatological treatments offered through commercial healthcare services.

3. Vellore Citizens' Welfare Forum v. Union of India (1996) 5 SCC 647

The Supreme Court recognised the precautionary principle and polluter-pays principle as important components of Indian environmental law.

These principles are relevant to the environmental risks associated with manufacturing, handling, and disposing of biological materials used in microbiome research.

4. A.P. Pollution Control Board v. Prof. M.V. Nayudu (1999) 2 SCC 718

The Supreme Court emphasised the importance of scientific expertise in environmental decision-making.

The judgment is relevant to regulatory assessment of engineered microorganisms and other microbiome technologies where scientific uncertainty requires specialised evaluation.

5. Justice K.S. Puttaswamy (Retd.) v. Union of India (2017) 10 SCC 1

The Supreme Court recognised privacy as a fundamental right under Article 21 and other constitutional freedoms.

The decision is particularly relevant to dermatological microbiome research involving identifiable medical records, genetic information, and sensitive biological datasets.

Regulatory safeguards and compliance measures

Effective governance requires coordinated scientific, ethical, and legal supervision.

Important safeguards include:

Establishing clear product classification standards.

Conducting appropriate preclinical and clinical safety assessments.

Obtaining informed consent from research participants.

Maintaining microbial identity and quality-control records.

Monitoring contamination and unexpected biological effects.

Protecting identifiable medical and microbiome information.

Requiring scientific evidence for therapeutic advertising claims.

Establishing procedures for reporting adverse events.

Ensuring appropriate disposal of biological materials.

Regulatory authorities should also encourage cooperation between dermatologists, microbiologists, biotechnology researchers, manufacturers, and public health institutions.

Conclusion

Dermatological microbiome interventions represent an emerging area of biotechnology with potential applications in skin health and disease management. However, their development requires a balanced governance framework addressing clinical safety, product classification, informed consent, environmental protection, consumer rights, and data privacy. Indian legislation provides several regulatory foundations, including the Drugs and Cosmetics Act, 1940, the New Drugs and Clinical Trials Rules, 2019, and the Environment (Protection) Act, 1986. Judicial decisions concerning informed consent, consumer protection, environmental precaution, and privacy offer important legal guidance. Strong scientific oversight and transparent regulation are essential for ensuring responsible development of microbiome-based dermatological treatments.